Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values

Clinical Chemistry

Volumn 47, Issue 10, 2001, Pages 1776-1781

  Sjogren M ^a   Vanderstichele, H ^a   Agren H ^a   Zachrisson, O ^a   Edsbagge, M ^a   Wilkkelso C ^a   Skoog, I ^a   Wallin, A ^a   Wahlund, L O ^a   Marcusson, J ^a   Nagga K ^a   Andreasen, N ^a   Davidsson, P ^a   Vanmechelen, E ^a   Blennow, K ^a  

^a Institute of Clinical Neuroscience   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL HEALTH; NORMAL HUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REFERENCE VALUES;

EID: 0034741554     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.10.1776     Document Type: Article

References (47)

1. Clinical diagnosis of Alzheimer's disease: Report on the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease
2. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
3. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice
4. Tau protein and the neurofibrillary pathology of Alzheimer's disease
5. Both total and phosphorylated tau are increased in Alzheimer's disease
6. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
7. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?
8. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
9. Increased cerebrospinal fluid tau in patients with Alzheimer's disease
10. Tau in cerebrospinal fluids: Establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau
11. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
12. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type
13. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease
14. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
15. Combination of tau/phospho-tau with other biochemical markers for Alzheimer CSF diagnosis and tau in CSF as marker for neurodegeneration
16. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
17. CSF tau and Aβ42: Logical biomarkers for Alzheimer's disease?
18. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
19. CSF levels of tau, β-amyloid42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
20. Tau protein in cerebrospinal fluid: A new diagnostic and prognostic marker in Alzheimer disease?
21. Amyloid β protein 1-42/43 (Aβ1-42/43) in cerebellar diffuse plaques: Enzyme-linked immunosorbent assay and immunocytochemical study
22. Cerebrospinal fluid β-amyloid (1-42) in Alzheimer's disease: Differences between early- and late-onset AD and stability during the course of disease
23. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
24. Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
25. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician
26. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio
27. Principles of albumin and IgG analysis in neurological disorders
28. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: Identification of phosphorylation sites in tau protein
29. Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes
30. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF
31. Standardization of measurement of β-amyloid (1-42) in cerebrospinal fluid and plasma
32. Approved recommendation on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits
33. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls
34. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stoke
35. Absolute number of neurons and thickness of the cerebral cortex during aging, senile and vascular dementia, and Pick's and Alzheimer's diseases
36. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study
37. Neuron loss in the aging visual cortex of man
38. Cell counts in human cerebral cortex in normal adults throughout life using an image analysing computer
39. The effect of advanced old age on the neurone content of the cerebral cortex. Observations with an automatic image analyser point counting method
40. Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age
41. Neocortical cell counts in normal human adult aging
42. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid
43. CSF-tau and CSF-AB42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
44. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke
45. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid